CONMED Co. (NYSE: CNMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $107.00 price target on the stock.
CONMED Corporation to Present at the BofA Securities Healthcare Conference
CONMED Corporation (NYSE:CNMD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates [Yahoo! Finance]
CONMED Co. (NYSE: CNMD) had its price target lowered by analysts at JPMorgan Chase & Co. from $115.00 to $75.00. They now have an "overweight" rating on the stock.